Natera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 04, 2022 at 04:05 pm EDT
Share
Natera, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 198.2 million compared to USD 142.03 million a year ago. Net loss was USD 145.15 million compared to USD 116.03 million a year ago. Basic loss per share from continuing operations was USD 1.5 compared to USD 1.32 a year ago. Diluted loss per share from continuing operations was USD 1.5 compared to USD 1.32 a year ago.
For the six months, revenue was USD 392.33 million compared to USD 294.34 million a year ago. Net loss was USD 283.75 million compared to USD 179.88 million a year ago. Basic loss per share from continuing operations was USD 2.95 compared to USD 2.06 a year ago.
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
NATERA, INC. 
